摘要
目的:研究健康受试者口服米氮平受试片和参比片(瑞美隆)的生物等效性。方法:21例健康男性志愿受试者单剂量随机交叉口服30 mg米氮平受试片和参比片,采用LC-MS法测定给药后不同时间的血浆中米氮平的浓度,用BAPP2统计软件非房室模型法估算药动学参数,并作方差分析及双单侧t检验,对米氮平受试片和参比片进行生物等效性评价。结果:受试者口服米氮平受试片和参比片后的Cmax分别为(105.70±30.83)和(107.44±30.47)μg·L-1,Tmax分别为(1.9±0.8)和(1.7±0.7)h,t1/2分别为(21.45±6.63)和(21.52±9.31)h,AU0-120h分别为(1 385.11±503.13)和(1 440.19±547.47)μg·h·L-1,AUC0-∞分别为(1 435.87±510.13)和(1 440.19±547.47)μg·h·L-1,MRT分别为(23.55±7.08)和(24.66±12.3)h。以AUC0-120h估算,受试制剂对参比制剂的相对生物利用度为(104.10±27.40)%。结论:米氮平受试片与参比瑞美隆片生物等效。
Objective: To study the pharmacokinetics and bioequivalence of mirtazapine tablets in healthy volunteers. Methods:A LC-MS method was used for the determination of mirtazapine in plasma after a single oral dose of 30 mg mirtazapine test or reference samples in a crossover design. The pharmacokinetic parameters as well as relative bioavailability were analyzed based on a non-compartment model of BAPP2 statistical software, variation analyses and a two-sided t-test. Results: The main pharmacokinetic parameters of mirtazapine test and reference tablets were as follows : C,ax ( 105.70 ± 30. 83 ) vs. (107.44±30.47)μg·L^-1,Tmax(1.9 ±0.8) vs. (1.7 ±0.7)h,t1/2(21.45 ±6.63) vs. (21.52 ± 9.31)h, AUC0-120h(1435.87 ±510.13)vs. (1 440. 19 ±547.47)μg·h·L^-1, AUC0-∞ (1 435.87 ± 510. 13) vs. (1 440. 19 ±547.47)μg·h·L^-1 ,and MRT (23.55 ±7.08) vs. (24. 66 ± 12. 3)h, respectively : the P value of these parameters shows no statistical difference ( P 〉 0.05 ). The relative bioavailability of the test to reference lablets was( 104. 10 ± 27.40)%. Conclusions: The test mirtazapine tab- lets are bioequivalent to reference mirtazapine. The reliable,simple and sensitive LC-MS method was applied to evaluate plasma mirtazapine concentrations.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2006年第15期1299-1302,共4页
Chinese Journal of New Drugs
关键词
米氮平片
液相-质谱联用
药动学
生物等效性
mirtazapine tablet
liquid chromatograph-mass spectrometer ( LC-MS )
pharmacokinetics
bioequivalence